Did you miss IGCS 2019 in Rio? Were you there and could not attend all the talks you wanted to? Like every meeting there was an abundance of excellent presentations including new research, clinical trials and review sessions.
See more: View over 150 presentations from the 2019 Annual Global Meeting.

This month we highlight two sessions from Rio which we hope you will find interesting and relevant to your practice.

Translating Endometrial Molecular Risk Stratification To Endometrioid Ovarian Carcinoma: A Novel Application Of Precision Medicine
Dr. Pauline Kramer and colleagues applied the validated Proactive Molecular risk Classifier for Endometrial cancer (ProMisE) to an international cohort of over 500 well characterized endometrioid ovarian carcinomas. All four molecular subtypes were identified (POLEmut, mismatch repair deficient (MMRd), p53wt/NSMP and p53abnormal(p53abn)), and molecular subtype was associated with clinical outcomes (PFS, DSS) including no recurrence events within POLEmut at 10 years and very poor outcomes within p53abn (only ~ 50% survival at 10 years). Association of outcomes with ProMisE was maintained on multivariable analysis. Possible utility of this molecular framework to endometriosis-associated ovarian carcinomas is discussed.

Concerv: A Prospective Trial Of Conservative Surgery For Low-Risk Early Stage Cervical Cancer
Dr. Kathleen Schmeler shares the results of an international collaborative prospective single arm study assessing the safety and feasibility of simple (non-radical) hysterectomy or cone biopsy with lymph node (LN) assessment for early stage cervical carcinoma and with favorable pathology characteristics. Final analysis includes 100 patients with a 4.3% recurrence rate observed thus far. Lymph node (LN) involvement was diagnosed in 5% of women confirming the importance of LN assessment. Further follow-up is needed to determine if long-term oncologic outcomes are comparable to women who had undergone radical procedures and two additional prospective studies (SHAPE, GOG 278) in early cervical carcinoma are pending which will also help clarify if less aggressive surgical approach is safe.

Leave a Reply